Other competitors in the biotech space that use AI include Xaira Therapeutics, which has raised over $1 billion in funding and San Fransico-based Insitro, which has raised over $600 million in venture capital funding.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, a machine learning-powered drug discovery and development company, today announced the appointment of Emily Fox, Ph.D., as senior vice president of AI/machine learning. In this role, she will oversee those areas as well as data science and computational biology, inclusive of data modalities that span genetics, omics, imaging, clinical data, and molecular design. Dr. Fox, a professor in the Department of Statistics and Department of Computer Science at Stanford University, has made groundbreaking contributions in the application of machine learning in healthcare, with her pioneering work directly translating into patient impact. "AI leaders of Emily’s caliber who simultaneously have an understanding of biology and health are rare, and we are privileged to have recruited her to lead our AI/ML teams,” said Daphne Koller, Ph.D., co-founder and CEO. “Her groundbreaking work in machine learning, alongside her track record in translating research into impactful applications in healthcare, aligns perfectly with our mission to revolutionize drug discovery through data-driven approaches

insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company's board of directors.